drugset / Trial / NCT05669625
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine
Phase 3
Active not recruiting
12440 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collabJiangsu Province Centers for Disease Control and Prevention · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.
Timeline
- Start
- 2022-12-26
- Primary completion
- 2024-04-14
- Completion
- 2026-09-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Live Attenuated Varicella Vaccine | Vaccine | 0.5 ml | Subcutaneous |